Analyses of data from the TRACERx cohort of Lung Cancer patients – Nature Cell Biology
A recent paper by Wei-Ting Lu, Kwok Research Fellow at the Francis Crick Institute, was mentioned by Nature Cell Biology on X:
Authors: Wei-Ting Lu, Lykourgos-Panagiotis Zalmas, Chris Bailey, Jiri Bartek, Nnennaya Kanu, Charles Swanton et al.
“New by Wei-Ting Lu, Charles Swanton, Nnennaya Kanu, Jiri Bartek and co: analyses of data from the TRACERx cohort of Lung Cancer patients delineate how FAT1 regulates HR repair, chromosomal instability and whole-genome doubling with distinct mechanisms.”
Amy Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared this post, adding:
“New driver mutation (FAT1) in lung cancer. Analysis of TRACERx cohort by Charles Swanton and colleagues.”
More posts featuring Nature Cell Biology and Amy Moore.
Wei-Ting Lu is a Kwok Research Fellow at The Francis Crick Institute, studying cancer evolution and chromosomal instability in tumor progression and therapy resistance. His current research focuses on FAT1 mutations in lung cancer and their role in genomic instability, as well as TRACERx driver mutations and their impact on DNA repair.
With over 13 years of expertise in molecular biology, his work spans oncology, DNA damage response, protein translation, and the microRNA pathway.
Dr. Amy C. Moore is the Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation. She previously served as the Director of Science and Research at the Addario Lung Cancer Medical Institute (ALCMI).
She has published peer-reviewed papers on virology, cancer, and biomarker testing in NSCLC. Dr. Moore is also an expert on COVID-19’s impact on lung cancer and serves on several advisory boards.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023